On August 9, 2012, Perrigo announced that it has received final approval from the FDA for its abbreviated new drug application for clobetasol propionate shampoo, 0.05%, the generic equivalent of Clobex Shampoo. Perrigo will commence shipment of the product immediately.
Clobetasol propionate shampoo, 0.05%, is indicated for the treatment of moderate to severe scalp psoriasis. Brand and Generic annual sales were approximately $57 million, as measured by Wolters Kluwer Health.
Clobetasol propionate is a corticosteroid used to treat various skin disorders including eczema and psoriasis. It is also effective for contact dermatitis caused by exposure to poison ivy/oak. Clobetasol belongs to US Class I (Europe: class IV) of the corticosteroids, making it one of the most potent available. It comes in shampoo, mousse, ointment and emollient cream presentations. It is also used to treat several auto-immune diseases including alopecia areata, vitiligo and auto immune skin nodules.